What Seattle Needs (Part 3): Working Together to Revitalize Biotech

Stewart Lyman

These are incredibly exciting times in biomedical research. Though the biopharmaceutical industry is in flux, prospects for a greater understanding of the disease process, and the development of …

What Seattle Needs (Part 2): Dealing With Amgen’s Upcoming Departure

Stewart Lyman

Reality bites: Amgen’s (NASDAQ: AMGN) decision to leave Washington state is a serious blow to our local bioscience ecosystem. Those who think that all of those people …

What Seattle Needs (Part 1): “Semi-Successful” Biotech Companies

Stewart Lyman

I know what you’re thinking: that’s a pretty strange headline. Why would a city want to attract or build companies that are only “semi-successful?” Wouldn’t it want …